MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Bristol-Myers Squibb Company ROE Ratio 2011-2026 | BMY
Annual ROE Ratio Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.19 | -54.78 | 27.27 | 20.37 | 19.46 | -23.84 | 6.65 | 34.83 | 8.5 | 27.26 | 10.85 | 13.38 | 16.82 | 14.37 | 23.38 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 38.19 | -54.78 | 12.18 |
Quarterly ROE Ratio Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.58 | -41.17 | -48.64 | -49.23 | -51.99 | 25.16 | 23.42 | 20.99 | 13.01 | 17.16 | 12.36 | 15.22 | 12.39 | -14.12 | -13.32 | -16.41 | -23.84 | 0.63 | -1.7 | 1.3 | 6.66 | 16.98 | 27.91 | 27.79 | 35.07 | 6.97 | 0.62 | 5.76 | 8.58 | 33.93 | 34.16 | 33.57 | 27.55 | 20.64 | 18.16 | 10.04 | 10.97 | 12.44 | 12.34 | 15.5 | 13.49 | 18.2 | 17.91 | 19.2 | 16.91 | 18.91 | 9.13 | 10.32 | 14.39 | 12.94 | 24.23 | 25.15 | 23.25 | 6.07 | 5.65 | 6.18 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 38.58 | -51.99 | 9.42 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M |  USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
AbCellera Biologics
ABCL
|
-15.14 | $ 3.55 | -2.18 % | $ 1.06 B |  Canada |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
ADMA Biologics
ADMA
|
30.78 | $ 15.66 | -5.32 % | $ 3.73 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Aptorum Group Limited
APM
|
-20.19 | $ 0.82 | -0.73 % | $ 4.47 M | China |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-51.87 | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
6.05 | $ 20.16 | 1.51 % | $ 2.54 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
-4.59 | $ 75.5 | -1.35 % | $ 1.46 B | USA |
 |
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.48 | -9.2 % | $ 378 M | Britain |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Athersys
ATHX
|
-531.22 | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
15.38 | $ 34.35 | -3.75 % | $ 3.57 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
645.98 | $ 7.8 | -7.36 % | $ 33.8 M | USA |
 |
CorMedix
CRMD
|
-66.06 | $ 6.32 | -11.24 % | $ 322 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-116.29 | - | - | $ 521 M | USA |
 |
Champions Oncology
CSBR
|
124.63 | $ 5.79 | -3.58 % | $ 79.1 M | USA |
 |
Axsome Therapeutics
AXSM
|
-207.46 | $ 160.44 | -2.22 % | $ 7.98 B | USA |
 |
BridgeBio Pharma
BBIO
|
35.13 | $ 65.38 | -1.74 % | $ 12.5 B | USA |
 |
Denali Therapeutics
DNLI
|
-34.38 | $ 19.69 | -3.34 % | $ 3.24 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
149.7 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Edesa Biotech
EDSA
|
-311.44 | $ 3.8 | -10.9 % | $ 12.2 M | USA |
 |
Equillium
EQ
|
-59.08 | $ 1.79 | 2.0 % | $ 62.2 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-1239.35 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-69.02 | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
-782.6 | - | -74.18 % | $ 955 K | USA |
 |
BioLineRx Ltd.
BLRX
|
-136.27 | $ 2.75 | -2.14 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
5.73 | $ 60.47 | 0.07 % | $ 11.6 B | USA |
 |
Eton Pharmaceuticals
ETON
|
-6.05 | $ 17.04 | -2.77 % | $ 437 M | USA |